Psychedelics and PTSD

MDMA is showing promise for treating PTSD, particularly among veterans and survivors of abuse, with a potential path towards prescription use in supervised settings. Psilocybin is also gaining traction, demonstrating significant efficacy for end-of-life depression and possibly major depressive disorder. Ongoing studies, like one at Johns Hopkins, are exploring its effects on treatment-resistant depression, highlighting a shift in the scientific community's approach to mental health therapies.